A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144 (Supplement 1), p.989-989
Main Authors: Chavez, Julio C., Olszewski, Adam J., Bastos-Oreiro, Mariana, Assouline, Sarit E., Lossos, Izidore S., Diefenbach, Catherine, Ghosh, Nilanjan, Modi, Dipenkumar, Sabry, Waleed, Naik, Seema, Shah, Nirav N., Foley, Ronan, Hodson, Daniel J, Makadia, Sneha, Pham, Song, Penuel, Elicia, Wu, Hao, Ead, Wahib S., To, Iris, Batlevi, Connie Lee, Wei, Michael C., Budde, L. Elizabeth
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2024-194581